

Re-Amendment
210
Dr

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Hodge, Martin

Serial No.: 09/965,313

Filed: September 26, 2001

For: NOVEL IL9/IL2 RECEPTOR_LIKE MOLECULES AND USES THEREFOR

Group Art Unit: 1644

Examiner: NOT YET ASSIGNED

Assistant Commissioner for Patents


Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

December 4, 2001

Date of Signature and of Mail Deposit


Kerri Pollard Schray

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination of the above referenced application, please amend the specification as follows:

At page 6, line 29 through page 7, line 5, please replace the paragraph with the following:

Figure 1A and 1B shows the amino acid sequence alignment for the human and murine 16445 proteins (SEQ ID NO:2 and SEQ ID NO:4, respectively) encoded by human 16445 (SEQ ID NO:1) and its murine orthologue 16445 (SEQ ID NO:3) with the human IL-2 receptor beta chain (hIL-2Rb; SP Accession Number P14784; SEQ ID NO:5), murine IL-2 receptor beta chain (mIL-2Rb; SP Accession Number P16297; SEQ ID NO:6), human IL-9 receptor (hIL-9R; SP Accession Number Q01113; SEQ ID NO:7), and murine IL-9 receptor (mIL-9R; SP Accession Number Q01114; SEQ ID NO:8). The sequence alignment was generated using the Clustal method.

At page 13, lines 12 through 17, please replace the paragraph with the following:

The h16445 protein displays similarity to the human IL-2 receptor beta chain (SEQ ID NO:5; approximately 36.9% identity over a 130 amino acid overlap), the murine IL-2 receptor